Double-blind Study

News

Related Video News

No related video news stories found.

Organic Broadcast Project

Related Videos

No related videos found.

Study tests if protein regrows spinal disks to avoid back surgeries

Published December 2, 2008, 9:12 am, KY3 Springfield

Many people suffer the debilitating effects of lower back pain. Relief could prove to be a shot away.

Discover News | Full Story


Patient Enrolment Completed in Phase II Clinical Trial for Allon's AL-108

Published December 2, 2008, 8:59 am, T-Net British Columbia

Vancouver, BC, December 2, 2008--(T-Net)--Allon Therapeutics Inc. (TSX:NPC) announced today that patient enrolment is complete in a Phase II clinical trial evaluating the safety and efficacy of the Company's proprietary drug candidate AL-108 in patients with schizophrenia-related cognitive impairment.

Discover News | Full Story


Landmark EchoCRT Trial Enrolls First European Patients

Published December 2, 2008, 8:32 am, Centre Daily Times

BIOTRONIK announced that the first European patients have been enrolled into the EchoCRT (Echocardiography guided Cardiac Resynchronization Therapy) trial by the team of physicians at Hospital Clínic in Barcelona, Spain, led by Professor Dr. Josep Brugada, Director of the Thorax Institute, Chairman of the Cardiology Department, EchoCRT Executive Committee Member and President of the European ...

Discover News | Full Story


Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints

Published December 2, 2008, 8:27 am, EurekAlert!

( WeissComm Partners ) Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT 501, met all primary endpoints. HZT 501, a novel, proprietary fixed-dose combination product containing ibuprofen and famotidine, demonstrated a statistically significant reduction in the ...

Discover News | Full Story


Landmark EchoCRT Trial Enrolls First European Patients

Published December 2, 2008, 8:06 am, Business Wire via Yahoo! Finance

BERLIN----BIOTRONIK announced that the first European patients have been enrolled into the EchoCRT trial by the team of physicians at Hospital Clínic in Barcelona, Spain, led by Professor Dr.

Discover News | Full Story


Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting ...

Published December 2, 2008, 6:27 am, PR Newswire via Yahoo! Finance

176b in Atrial Fibrillation Included in Scientific Program

Discover News | Full Story


Protalix BioTherapeutics Announces Completion of Enrollment for its Pivotal Phase III Clinical Trial of Gaucher Disease

Published December 2, 2008, 6:17 am, Centre Daily Times

Protalix BioTherapeutics, Inc. (Amex: PLX), announced today that it has completed enrollment in the Company’s pivotal phase III clinical trial of prGCD, a proprietary plant cell expressed recombinant form of human glucocerebrosidase (GCD) for the treatment of Gaucher disease. Gaucher disease is a rare and serious lysosomal storage disorder in humans.

Discover News | Full Story


Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints

Published December 2, 2008, 5:30 am, PR Newswire via Yahoo! Finance

Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that two pivotal Phase 3 trials evaluating its lead investigational product candidate, HZT-501, met all primary endpoints.

Discover News | Full Story


TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients ...

Published December 2, 2008, 5:30 am, PR Newswire via Yahoo! Finance

TorreyPines Therapeutics, Inc. today announced positive results from a 26 patient Phase II trial evaluating three doses of NGX267 as a treatment for xerostomia, or dry mouth, in patients with Sjogren's syndrome.

Discover News | Full Story


Protalix BioTherapeutics Announces Completion of Enrollment for its Pivotal Phase III Clinical Trial of Gaucher Disease

Published December 2, 2008, 5:30 am, Business Wire via Yahoo! Finance

CARMIEL, Israel----Protalix BioTherapeutics, Inc. , announced today that it has completed enrollment in the Company’s pivotal phase III clinical trial of prGCD, a proprietary plant cell expressed recombinant form of human glucocerebrosidase for the treatment of Gaucher disease.

Discover News | Full Story



News Directory

Get started fast by using a pre-defined news directory category

Breaking News
and Top Stories
Business
Earnings, Economy, Personal Finance, and Stock Markets
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss
Politics
Congress, Supreme Court, and White House
Science
Animals, Astronomy, Biotechnology, Space, and Weather
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis
Technology
Communications, Hardware, Internet, Personal Technology, and Software
United States
and Crimes and Trials
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East


© Copyright 2005-2006 News Meme, All Rights Reserved | More News | Link Index | OSWD Design

Powered by Odin Assemble 2.5a